Edition:
India

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

3.51USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$3.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
291,638
52-wk High
$6.66
52-wk Low
$3.33

Latest Key Developments (Source: Significant Developments)

Ziopharm Oncology To Initiate Pivotal Trial Of Cancer Treatment in Second Half of 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Ziopharm Oncology Inc ::ZIOPHARM ONCOLOGY PROVIDES UPDATE ON STANDOUT TECHNOLOGIES DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ZIOPHARM ONCOLOGY - UPDATED GUIDANCE ON PLANNED PIVOTAL TRIAL TO EVALUATE CONTROLLED IL-12 AND ANNOUNCED THAT IT WILL INITIATE IN SECOND HALF OF 2018.  Full Article

Ziopharm Oncology reports third quarter financial results
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports third quarter 2017 financial results and provides update on recent activities.Q3 loss per share $0.13.Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.  Full Article

Ziopharm Q2 loss per share $1.01
Wednesday, 10 Aug 2016 

Ziopharm Reports Second : Q2 loss per share $1.01 . Quarter 2016 financial results and provides update on recent activities . Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S .Ziopharm oncology inc says recognized approximately $1.7 million in revenue during quarter in comparison with $0.3 million in revenue in 2015.  Full Article

Ziopharm Oncology updates on early study for brain cancer drug
Friday, 15 Jul 2016 

Ziopharm Oncology Inc : Ziopharm issues statement regarding phase 1 study of gene therapy candidate ad-RTS-hIL-12 in brain cancer . "first two patient deaths, which occurred 6.7 months and 3.9 months after treatment, were unrelated to study drug" . "for patients that remain in follow up in this phase i study, we believe that preliminary overall survival remains encouraging" . Third death has just been reported, collecting and analyzing information in order to properly and timely report it to fda . There have been no reported related instances of brain hemorrhage in pervious cohort or prior studies with ad-RTS-hIL-12 + veledimex . Cause of death for third patient is intracranial hemorrhage, which occurred some time after patient had been discharged from treating center .Enrollment remains open in study, will be discussing with safety review committee appropriate course of action.  Full Article

Intrexon and Ziopharm amend exclusive channel collaborations
Thursday, 30 Jun 2016 

Ziopharm Oncology Inc : Intrexon and Ziopharm amend exclusive channel collaborations to improve alignment as programs advance through development . New structure is intended to facilitate increased investment in clinical development by Ziopharm .Announced amendments to their exclusive channel collaborations (ECCS) in fields of oncology and graft-versus-host-disease.  Full Article